Fig. 1: Consort diagram for the T-DM1/Pertuzumab, THP, and control populations. | Nature Communications

Fig. 1: Consort diagram for the T-DM1/Pertuzumab, THP, and control populations.

From: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Fig. 1: Consort diagram for the T-DM1/Pertuzumab, THP, and control populations.The alternative text for this image may have been generated using AI.

Consort diagram shows the number of patients screening, randomized, and receiving allocated therapy from the start of I-SPY2 to the close of the T-DM1/Pertuzumab and THP arms. I-SPY2 is modified intent-to-treat, where patients receiving their allocated therapy are considered evaluable for analysis.

Back to article page